このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

FIND HFリスクガイドによる心不全スクリーニング - パイロットスタディ (FIND HF)

2026年9月30日 更新者:Prof Christopher Gale、University of Leeds

FIND HF:リスク誘導型心不全スクリーニング

The goal of this clinical trial is to learn if the FIND HF algorithm detection rates of heart failure during testing are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk in a population identified as at risk of undiagnosed heart failure. The main questions it aims to answer are:

  • Are people who are identified as high risk by the FIND-HF tool more likely to be diagnosed with heart problems during testing than those identified as low risk?
  • Are people identified as high risk by the FIND-HF tool more likely to show signs of heart problems during testing than those identified as low risk?? Researchers will compare patients in the high risk and low risk groups to see if more patients are detected with asymptomatic heart failure in the high risk group compared to the low risk group.

Participants will attend one visit at a local clinic where they will undergo an NT proBNP blood test which indicates heart failure and an echocardiogram to evaluate the heart's chambers, valves and overall function to help diagnose various heart conditions.

調査の概要

状態

招待による登録

条件

詳細な説明

Background Heart failure (HF) affects around 1-2% of adults globally and is a leading cause of unplanned hospital admissions, especially among older people. In the UK alone, over one million people have HF, with about 200,000 new cases each year. This increase is mainly due to an aging population and better survival rates following heart attacks.

From the perspective of treatment, there are three main categories of HF:

  • HF with reduced ejection fraction (HFrEF)
  • HF with mid-range ejection fraction (HFmrEF)
  • HF with preserved ejection fraction (HFpEF) For HFrEF, four pillar therapy (diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, lanoxin) is established as the gold standard for pharmacotherapeutic management, helping to reduce the risk of death and hospital admissions. For HFpEF and HFmrEF, medications like empagliflozin, dapagliflozin, and finerenone have shown promising results in reducing risks. New drugs like Semaglutide and Tirzepatide are also beneficial for HFpEF patients with obesity. There are now more treatment options for HF than ever before.

In the UK, nurse-led teams in the community are capable of initiating and adjusting HF treatments. However, diagnosing HF early, before severe symptoms appear, remains challenging. Current guidelines recommend specific tests for diagnosis, but many (8 out of 10) diagnoses are still made in hospitals, often late.

The NHS aims to improve early diagnosis in primary care to reduce hospital admissions and improve patients' quality of life.

Funded by the British Heart Foundation (BHF) the investigators have developed an AI algorithm, FIND-HF, to identify people at risk of undiagnosed HF using data from routinely collected electronic health records.

Aims of the project The research project aims to determine the effectiveness of the FIND-HF AI algorithm in identifying HF at different risk levels and to understand the potential benefits of early detection and treatment.

The investigators will quantify the burden of symptoms, natriuretic peptide levels, and diagnostic yield of asymptomatic left ventricular systolic dysfunction, HFrEF, HFmrEF, and HFpEF at different FIND-HF AI risk scores. Using this information, the investigators will establish the risk score threshold that would be used for a future randomised clinical trial (RCT) of early detection of HF.

In addition, amongst patients newly diagnosed with HF during the study, the investigators seek to quantify the pharmacological treatment opportunities to inform the potential effect size, and thus sample size, of a future RCT of early detection and treatment of HF to reduce heart failure hospitalisation and cardiovascular death.

Identification of participants and recruitment Participants will be identified through by having their HF risk estimated their primary care electronic health records.

Individuals will be divided into two categories based on the predicted HF risk with recruitment 1:2 guided by risk strata, with 151 participants in the top 10 percentiles of risk, and 302 participants from the bottom 90 percentiles. This approach aims to enrich the cohort with higher risk patients while also including lower risk patients to determine whether there is an increase in the yield of new HF diagnosis from across the range of FIND-HF AI risk estimates.

Study invitations will be sent to eligible participants in each risk category in batches until the target sample size is reached. The invitation process will consist of a text message followed by an information pack in the post including a participant information sheet, consent form, contact information form and freepost return envelope. Participants will return the consent form and contact information to the research team who will then contact them to make an appointment for the study visit. The study visit will take place at the participant's GP surgery or a community-based health hub.

All participants will be required to provide written informed consent. Study visit

Consenting participants will attend one study visit. During the visit, a British Society of Echocardiography (BSE)-accredited clinical member of the research team will carry out the following tests/investigations:

  • Medical history and symptom assessment (breathlessness, orthopnea, paroxysmal nocturnal dyspnea, exercise intolerance, fatigue, ankle swelling)
  • Height, Weight, HR and BP
  • Natriuretic peptide testing: Participants will undergo point of care (POC) natriuretic peptide testing
  • Echocardiography: Participants will receive an AI-enabled hand-held echocardiogram using the Kosmos device and US2.ai automated measurements.

New cases of HF will be reported to the participant and their GP. Their GP will have responsibility to refer the participant as per local protocol.

Follow up Participants will be followed up remotely through their primary care EHRs at 6 months, and 1-, 5- and 10-years from their study visit by a member of the research team. Follow-up will include assessment of HF therapy and HF events. Consent will be sought for linkage to secondary care records, death certificate data and national registries.

Expected value of results The NHS Major Conditions Strategy stresses the need for evolving care models to better serve the public, with a focus on early diagnosis of cardiovascular disease using AI and digital technology. This proof-of-concept study will inform the design of a trial to test AI risk stratification and community-based pathways for early diagnosis and treatment of heart failure (HF), aiming to reduce HF events and cardiovascular death. If successful, the AI model (FIND-HF) could be implemented across UK primary care for a community-based early HF diagnostic pathway in the NHS.

研究の種類

観察的

入学 (推定)

475

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • West Yorkshire
      • Leeds、West Yorkshire、イギリス、LS2 9JT
        • University of Leeds

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients identified at risk of developing Heart Failure by the FIND HF algorithm and are aged 40 and over, living in the Yorkshire area.

説明

Inclusion Criteria:

Registered with a doctor practice that uses electronic health system to record patient medical notes Age at enrolment greater or equal to 40 Identified as at risk of developing Heart Failure

Exclusion Criteria:

Registered with a doctor practice that is participating in research studies relating to heart failure screening

  • Known diagnosis of HF
  • On the palliative care register
  • Unable to give written informed consent for participation in the study
  • Unable to adhere to the study requirements

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Patients at risk of developing Heart Failure

Patients will attend one visit with a Cardiology specialist Clinical research fellow who will carry out tests to detect Heart Failure

Algorithm developed by the research team to identify patients at risk of heart failure that is currently undetected.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
To determine whether detection rates of a composite of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk
時間枠:Through study completion, an average of 12 months from date of enrolment

Odds ratio of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF detection rates from intervention in people identified as high HF risk compared with people identified as low HF risk

Through study completion, an average of 12 months from date of enrolment

二次結果の測定

結果測定
メジャーの説明
時間枠
To determine if components of composite outcome during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk
時間枠:Through study completion, an average of 12 months from date of enrolment

Odds ratio for each component of the composite in in people identified as high HF risk compared with people identified as low HF risk

Through study completion, an average of 12 months from date of enrolment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Chris P. Gale, Yes、University of Leeds

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月24日

一次修了 (推定)

2027年7月1日

研究の完了 (推定)

2028年10月1日

試験登録日

最初に提出

2025年9月30日

QC基準を満たした最初の提出物

2026年1月19日

最初の投稿 (実際)

2026年1月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • FIND HF Pilot study
  • PG.25.12417 (その他の助成金/資金番号:British Heart Foundation)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Planning to commercialise algorithm

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する